Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abcellera Biologics, Inc. (ABCL)
:ABCL
RESEARCH TOOLSreports
Holding ABCL?
Track your performance easily
ABCL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.34 - $5.62
Previous CloseN/A
Volume1.71M
Average Volume (3M)2.99M
Market Cap
$868.38M
Enterprise Value$169.88M
Total Cash (Recent Filing)$10.44M
Total Debt (Recent Filing)$911.22K
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Feb 25, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding295,366,270
10 Day Avg. Volume3,699,487
30 Day Avg. Volume2,987,190
Standard Deviation0.17
R-Squared0.01
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)26.21
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.20
Enterprise Value/Revenue5.14
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$9.50Price Target Upside219.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
AbCellera Biologics News
PremiumCompany Announcements
AbCellera Biologics Reports Q3 2024 Financial Results
PremiumCompany Announcements
AbCellera Biologics Expands Partnership and Advances Pipeline
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentManagement confirmed 14 molecules from their pipeline are in the clinic and 95 initiated programs, highlighting active development efforts.
Financial StabilityStrong liquidity provides a runway of over three years and a key opportunity to expand the pipeline and partnership portfolio.
Strategic PartnershipsABCL is leveraging its large $800M+ liquidity position to cultivate an internal pipeline and high-value strategic partnerships.
Bears Say
Financial PerformanceAbCellera reported financial results that were below estimates, with a significant earnings per share miss due to a $32M non-cash R&D impairment charge.
Future ProspectsAnalysts have reduced research fees and removed future milestones due to limited visibility, suggesting uncertainty in the company's outlook.
RevenueABCL's revenue fell short of expectations, with no milestones achieved during the quarter, raising concerns about the company's financial health.
---
Ownership Overview
43.29% Insiders
0.41% Mutual Funds
0.05% Other Institutional Investors
55.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABCL FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was $2.33 and its highest was $5.62 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is $868.38M.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is Feb 25, 2025 which is in 35 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on Nov 04, 2024. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.124 by -$0.046.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 295,366,270 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.124. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in ABCL
---
AbCellera Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (219.87% Upside)
$9.50 (219.87% Upside)
Blogger Sentiment
Bullish
ABCL Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 105.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.64%
12-Months-Change
Fundamentals
Return on Equity
-15.55%
Trailing 12-Months
Asset Growth
-7.89%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
---
ABCL Company Deck
---
ABCL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed outlook. While AbCellera demonstrates strong liquidity and pipeline progress, the financials reveal increased losses and flat revenue growth. The transition to a clinical stage biotech and expansion in partnerships are positive, but financial challenges remain.Read More>---
ABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
---
ABCL Stock 12 Month Forecast
Average Price Target
$9.50
▲(219.87% Upside)
Technical Analysis
Allogene Therapeutics
―
Immunocore Holdings
―
Seres Therapeutics
―
Denali Therapeutics
―
Fate Therapeutics
―
Moderna
―
Best Analysts Covering ABCL
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-31.89%
reiterated a buy rating 3 months ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -31.89% per trade.
---